TheFly.com
ERAS
Erasca
$
()
Erasca reports Q4 EPS (20c), consensus (23c)
Capital One starts Erasca with Overweight into key data catalysts
Erasca initiated with bullish view at Capital One
Erasca downgraded to Neutral at BofA amid remaining uncertainty
BofA gets more bearish on Erasca, downgrades shares
Erasca receives FDA Fast Track Designation for naporafenib
Erasca price target lowered to $8 from $10 at H.C. Wainwright
Erasca achieves key milestones for naporafenib, ERAS-801
Erasca reports Q3 EPS (20c), consensus (22c)
Erasca initiated with a Buy at H.C. Wainwright
Erasca doses first patient in SEACRAFT-1 Phase 1b trial
Erasca reports Q2 EPS (21c), consensus (24c)
Erasca reports Q2 EPS (21c), consensus (24c)
Copyright ©1998-2024 Thefly.com LLC
